Date of Graduation


Degree Type

Capstone Project

Degree Name

Master of Science in Physician Assistant Studies

First Advisor

Annjanette Sommers


Dabigatran is an oral direct thrombin inhibitor approved by the US FDA for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Dabigatran is rapidly replacing traditional anticoagulants, such as warfarin, despite the fact that clinicians have very little experience with dabigatran induced bleeding and no reliable therapeutic agent to reverse its effects. Prothrombin complex concentrate is effective at reversing traditional anticoagulants as it contains clotting factors, including prothrombin, the precursor to thrombin. How effective is prothrombin complex concentrate in reversing the anticoagulant activity of dabigatran?